Full Press Release Details
IMMUTEP S TACTI-002 DATA TO BE PRESENTED
AT SOCIETY FOR IMMUNOTHERAPY OF CANCER 2020 ANNUAL MEETING
SYDNEY, AUSTRALIA 3 November 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the
Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce more mature interim data from its phase II TACTI-002 study of
eftilagimod alpha ( efti ) has been accepted as a late breaker poster presentation and poster walk for highly scored abstracts at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary 2020 Annual Meeting, which is
taking place as a virtual event from 9-14 November, US Eastern Standard Time (US EST).
leading member society of medical professionals dedicated to advancing cancer immunotherapy and biological therapy. Its Annual Meeting is a multidisciplinary educational and interactive conference focused on improving cancer patient outcomes.
Immutep s Poster Presentation:
| Abstract title: | A Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung (NSCLC) or head and neck carcinoma (HNSCC) | |
| Abstract #: | 790 | |
| Date & time: | Monday 9 November 2020, 8am US EST | |
| Presenter: | Dr Matthew Krebs, The Christie NHS Foundation Trust, Manchester, UK |
Immutep will make the poster presentation available on its website following its publication at SITC 2020.
TACTI-002 is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada). It is evaluating the combination of efti with
MSD s KEYTRUDA (or pembrolizumab, an anti-PD-1 therapy) in up to 109 patients.
Immutep is a globally active biotechnology
company that is a leader in the development of LAG-3 immunotherapies for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative
treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM) and the NASDAQ (IMMP) in the United States.
Immutep s current lead product candidate is eftilagimod alpha ( efti or IMP321 ), a soluble
LAG-3Ig fusion protein which is a first-in-class antigen presenting cell (APC) activator and is being explored in cancer and
Immutep Limited, Level 12, 95 Pitt
Street, Sydney NSW 2000
Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Further information can be found on the Company s website www.immutep.com
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+1 (212) 915.2564; tim@lifesciadvisors.com
This announcement was authorised for release by the Chief Executive Officer of Immutep Limited.
Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000